Presentations & Publications Corporate Presentation July 2021 Corporate Presentation July 15, 2021 Publications Metabolic Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria Source Puurunen et al, Communications Biology Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Source Charbonneau et al, Nature Metabolism Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nature Communications Source Nelson et al, Nature Communications Developing a new class of engineered live bacterial therapeutics to treat human diseases Source Charbonneau et al, Nature Communications An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Source Kurtz et al, Science Translational Medicine Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Source Isabella et al, Nature Biotechnology Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Source Kurtz et al, Clinical and Translational Science Immuno Oncology Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Source Leventhal et al, Nature Communications Presentations and Posters Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting June 10, 2021 A Novel Human IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease, Digestive Disease Week (DDW) May 23, 2021 Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021 Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019 22nd Annual Meeting of the American Society of Gene & Cell Therapy April 30, 2019 Email Alerts Contact IR RSS Feeds Print Page Email Page
Corporate Presentation July 2021 Corporate Presentation July 15, 2021 Publications Metabolic Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria Source Puurunen et al, Communications Biology Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Source Charbonneau et al, Nature Metabolism Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nature Communications Source Nelson et al, Nature Communications Developing a new class of engineered live bacterial therapeutics to treat human diseases Source Charbonneau et al, Nature Communications An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Source Kurtz et al, Science Translational Medicine Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Source Isabella et al, Nature Biotechnology Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Source Kurtz et al, Clinical and Translational Science Immuno Oncology Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Source Leventhal et al, Nature Communications Presentations and Posters Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting June 10, 2021 A Novel Human IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease, Digestive Disease Week (DDW) May 23, 2021 Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021 Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019 22nd Annual Meeting of the American Society of Gene & Cell Therapy April 30, 2019
Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria Source Puurunen et al, Communications Biology
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Source Charbonneau et al, Nature Metabolism
Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nature Communications Source Nelson et al, Nature Communications
Developing a new class of engineered live bacterial therapeutics to treat human diseases Source Charbonneau et al, Nature Communications
An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Source Kurtz et al, Science Translational Medicine
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Source Isabella et al, Nature Biotechnology
Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Source Kurtz et al, Clinical and Translational Science
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Source Leventhal et al, Nature Communications
Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021
Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021
Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting June 10, 2021
A Novel Human IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease, Digestive Disease Week (DDW) May 23, 2021
Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021
Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021
Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020
Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019
A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019
The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019